Mr. Feng Zhou has been our CEO and Chairman of the Board since July 4, 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017, he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services.  Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration. We believe that Mr. Zhou should serve as a member of our board of directors due to the perspective and experience he brings as our founder, Chairman, and CEO, and as our largest and controlling stockholder.

Mr. Jun Zheng will be appointed as our executive director of China SXT Pharmaceuticals, Inc. upon closing of the Nasdaq IPO. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004, and a department manager & a deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Jiangsu Suxuantang Pharmaceutical Co. Ltd.Mr. Zhengreceived his Bachelor degree from Jiangnan University (Wuxi Light Industry University) in 1999.

Dr. Junsong Li will be appointed as our independent director of China SXT Pharmaceuticals, Inc.  upon closing of the Nasdaq IPO. Dr. Li has over 20 year-experience in the TCM industry. He has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003, Dr. Li worked as an associate professor of Nanjing TCM Hospital. Dr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. He obtained his PhD from Shanghai TCM University in 2006. We believe Dr. Li is well-qualified to serve as a member of the board because of her extensive prior work experience and educational background in the TCM field. 

Mr. Wenwei Fan will be appointed as our independent director of China SXT Pharmaceuticals, Inc. upon closing of the Nasdaq IPO. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterHouseCoppers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jingsu University of Finance and Economics in 1992 with a bachelor’s degree.